<?xml version='1.0' encoding='utf-8'?>
<document id="1864259"><sentence text="[Role of pharmacogenetics in psychopharmacotherapy]." /><sentence text="Genetic polymorphism related to certain P450 isozymes, in particular the sparteine/debrisoquine oxygenase, is the dominant cause of interindividual variation in elimination of several drugs"><entity charOffset="83-95" id="DDI-PubMed.1864259.s2.e0" text="debrisoquine" /></sentence><sentence text=" If the pharmacokinetic variability is large, relative to the therapeutic index of the drug, the genetic polymorphism will be clinically important" /><sentence text=" If the dose cannot be adjusted on the basis of effect measurements, phenotyping may be a supplement or replacement for drug level monitoring which is otherwise relevant for such drugs" /><sentence text=" Several aspects as elucidated by the experience with the sparteine/debrisoquine oxidation polymorphism ought to be analysed: The role of active metabolites and their rate of formation and elimination, selective drug-drug interaction at the polymorphic isozyme or at alternative routes of elimination, the possible role of two or more polymorphic drug oxidation pathways, and the effect of saturable kinetics"><entity charOffset="68-80" id="DDI-PubMed.1864259.s5.e0" text="debrisoquine" /></sentence><sentence text=" The sparteine/debrisoquine oxidation polymorphism affects two major classes of drugs in psychopharmacology, the antidepressants and the neuroleptics, and this is the best example of clinical relevance of pharmacogenetic polymorphism"><entity charOffset="5-14" id="DDI-PubMed.1864259.s6.e0" text="sparteine" /><entity charOffset="15-27" id="DDI-PubMed.1864259.s6.e1" text="debrisoquine" /><pair ddi="false" e1="DDI-PubMed.1864259.s6.e0" e2="DDI-PubMed.1864259.s6.e0" /><pair ddi="false" e1="DDI-PubMed.1864259.s6.e0" e2="DDI-PubMed.1864259.s6.e1" /></sentence><sentence text=" Routine use of phenotyping thus should be considered for psychiatry departments" /><sentence text="" /></document>